Just wonder on everyone else's thoughts.
Another reason for lingering share price despite positive dsmb, we know 99.6% drugs fail, and some of those even make it through to phase 3 before failing. So based on that I'd think the market is still just waiting, thinking they have seen this before and putting no value to the trial results? So will it continue to linger here or slightly higher. Share issue, although also positive, has diluted the market price which hasn't helped.
The Future, page-21
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
